Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225036 · ClinicalTrials.gov registry record · NA

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

A NA study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Jordan Kharofa.

Recruiting
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT07225036 is a NA study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Jordan Kharofa. The registered enrollment target is 21 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225036, a NA study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Jordan Kharofa.

RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

Interventions

  • RADIATION LD-LRT

Study Locations (1)

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2025-12-15
Est. Completion 2029-12-15
Phase NA

Sponsor

Jordan Kharofa

2 total trials

What the Registry Record Tells You About NCT07225036

The ClinicalTrials.gov registry entry for NCT07225036 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Jordan Kharofa, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LD-LRT is the first listed.

NCT07225036 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07225036 about?

NCT07225036 is a clinical study titled "Promoting Immunotherapy Efficacy With Low-Dose Liver RT". The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

What is the current status of trial NCT07225036?

This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2025-12-15. Estimated completion is 2029-12-15.

What conditions does trial NCT07225036 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Liver Metastases, Low-Dose Liver Radiation (LD-LRT).

What interventions are being tested in trial NCT07225036?

The interventions under investigation include: LD-LRT (RADIATION).

Who is sponsoring clinical trial NCT07225036?

This trial is sponsored by Jordan Kharofa, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225036 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.